Latest filing published 10 Aug 2026 for Aptevo Therapeutics Inc..
Insider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Jeffrey G. Lamothe: trading record in brief
Jeffrey G. Lamothe is a declared insider of Aptevo Therapeutics Inc. (finance chief), with filings sourced from SEC (Form 4). Over a trading history stretching from 3 February 2017 to 6 August 2026, the count stands at 30 filings.
The filings describe grants, exercises and other transfers rather than trades on the open market. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
The newest entry dates from 10 August 2026: an option exercise, in Aptevo Therapeutics Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Jeffrey G. Lamothe
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 961 sharesCommon StockSEC:0001193125-26-343079:0
- 5 sharesCommon Stock (post-reverse split May ACTIVE)SEC:0000950170-25-097267:0
- 3 sharesCommon StockSEC:0000950170-25-032197:0
- 42 sharesCommon StockSEC:0000950170-24-094816:0
- 5,500 sharesCommon StockSEC:0000950170-24-025915:0
- 1,833 sharesCommon StockSEC:0000950170-24-009003:0
- 11,979 sharesCommon StockSEC:0001209191-23-045263:0
- 3,666 sharesCommon StockSEC:0001209191-23-016789:0
- 1,834 sharesCommon StockSEC:0001209191-23-005420:0
- 1,833 sharesCommon StockSEC:0001019056-22-000112:0
10 of 10 declarations